Haya Therapeutics
Total Raised
$28.54MInvestors Count
11Funding, Valuation & Revenue
7 Fundings
Haya Therapeutics's latest funding round was a Grant for $3.3M on May 3, 2022.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
5/3/2022 | Grant | $3.3M | 1 | |||
2/10/2022 | Seed VC - II | |||||
5/20/2021 | Seed VC | |||||
8/16/2018 | Biz Plan Competition - II | |||||
11/27/2017 | Incubator/Accelerator - II |
Date | 5/3/2022 | 2/10/2022 | 5/20/2021 | 8/16/2018 | 11/27/2017 |
|---|---|---|---|---|---|
Round | Grant | Seed VC - II | Seed VC | Biz Plan Competition - II | Incubator/Accelerator - II |
Amount | $3.3M | ||||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 1 |
Compete with Haya Therapeutics?
Ensure that your company and products are accurately represented on our platform.
Haya Therapeutics Investors
11 Investors
Haya Therapeutics has 11 investors. Innosuisse invested in Haya Therapeutics's Grant funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
5/3/2022 | 5/3/2022 | 1 Grant | Government | Switzerland | ||
5/20/2021 | 2/10/2022 | 2 Seed VC, Seed VC - II (2022) | Venture Capital | Massachusetts | ||
5/20/2021 | 2/10/2022 | 2 Seed VC, Seed VC - II (2022) | Corporate Venture | China | ||
Venture Capital | Switzerland | |||||
Venture Capital | Germany |
First funding | 5/3/2022 | 5/20/2021 | 5/20/2021 | ||
|---|---|---|---|---|---|
Last Funding | 5/3/2022 | 2/10/2022 | 2/10/2022 | ||
Investor | |||||
Rounds | 1 Grant | 2 Seed VC, Seed VC - II (2022) | 2 Seed VC, Seed VC - II (2022) | ||
Board Seats | |||||
Type | Government | Venture Capital | Corporate Venture | Venture Capital | Venture Capital |
Location | Switzerland | Massachusetts | China | Switzerland | Germany |
Compare Haya Therapeutics to Competitors
HAYA Therapeutics is a precision therapeutics company that discovers and develops tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer. The company’s discovery engine focuses on long, non-coding RNAs (lncRNAs) within the “dark matter” of the human genome – key tissue and cell-specific drivers of fibrosis and other disease processes – to identify targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA’s lead therapeutic candidate is an antisense molecule targeting Wisper, a cardiac-enriched master driver of fibrosis, which has shown in preclinical testing the ability to halt and potentially reverse the fibrotic processes underlying heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the tissue-specific treatment of fibrotic diseases in other tissues, including lungs, kidney, liver, and the micro-environment of solid tumor cancers. Haya Therapeutics was founded in 2019 and is based in Lausanne, Switzerland.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.